Treatment Response to Durvalumab Plus Tremelimumab after Progression with Previous Immune Checkpoint Inhibitor in Unresectable Hepatocellular Carcinoma
Investigational New Drugs（2024）
关键词
Hepatocellular carcinoma (HCC),Durvalumab plus tremelimumab,Atezolizumab plus bevacizumab,Immune checkpoint inhibitor (ICI)
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要